{
  "id": 21142577,
  "title": "Regeneron evp Marion McCourt sells $543,504 in stock",
  "url": "https://urgent.news/2026/11/22/regeneron-evp-marion-mccourt-sells-543-504-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-22T00:01:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/regeneron-evp-marion-mccourt-sells-543504-in-stock-93CH-5043636"
  },
  "original_language": "en",
  "account": null,
  "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) saw EVP Commercial Marion McCourt sell 566 shares of the company's common stock for a total of $543,504 on November 16, 2026. The sale occurred as Regeneron's stock was trading near its 52-week high of $991.73, following a strong 44% gain over the past six months. The shares were sold under a pre-arranged Rule 10b5-1 trading plan that McCourt adopted on February 17, 2026. Following the sale, McCourt directly holds 10,305 shares of Regeneron common stock, with an additional 219 shares held indirectly through a 401(k) Plan. Meanwhile, Regeneron reported strong sales of its leading product, Dupixent, which increased by 35% to $6.54 billion in the third quarter of 2026. The company also received FDA approval for Livsayis (cemdisiran) for treating generalized myasthenia gravis, and Truist Securities reiterating a Buy rating with a $982 price target.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}